Developer docs
API playgroundTry for free, no card

Search company profiles

EyeCRO

Full company profile

uuid000msf6

Namestring
EyeCRO
Legal namestring
EyeCRO LLC
Websiteurl
eyecro.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

EyeCRO LLC is a preclinical ophthalmic contract research organization founded in 2012 as a spin-off from Charlesson LLC and headquartered in Oklahoma City, Oklahoma, with a secondary research and development laboratory in Ann Arbor, Michigan. The company provides an integrated preclinical research platform for ophthalmic drug development, combining in-life efficacy studies, toxicology and pharmacokinetics, and in-house bioanalytical analysis (LC-MS/MS, HPLC, ELISA) under one roof, supported by 22+ validated disease models spanning retinal, corneal, inflammatory, and optic nerve indications across mouse, rat, and rabbit species. Both facilities hold full AAALAC International accreditation and EyeCRO has served over 400 companies and research institutions worldwide since inception.

The company's differentiator is the proprietary MiDROPS® microemulsion drug delivery technology, covered by broad US and international patents, which enables eyedrop delivery of lipophilic small molecules to both anterior and posterior segments of the eye. EyeCRO also offers EyeQ, a proprietary automated retinal ganglion cell quantification software, and provides specialized capabilities including dosing across multiple routes (intravitreal, subretinal, subconjunctival, topical), in-vivo ophthalmic imaging (ERG, OCT, fundus photography, fluorescein angiography), and histology services.

EyeCRO generates revenue through two streams: B2B contract research services delivered on a project-based, quote-based model to pharmaceutical and biotechnology sponsors (with named clients including SparingVision, Telios Pharma, InMed Pharmaceuticals, NeuMedics, and the National Eye Institute), and licensing of the MiDROPS platform to pharma partners for ophthalmic drug formulations, generating tiered single-digit royalties and development milestones. Distribution is direct enterprise sales, supported by presence at the ARVO Annual Meeting, scientific publications, and professional social media. The company is privately held and operates as a subsidiary of Charlesson LLC under CEO Dr. Rafal Farjo.

Short descriptiontext

EyeCRO is a preclinical ophthalmic contract research organization providing integrated in-life efficacy studies, bioanalytical services, and the proprietary MiDROPS microemulsion drug delivery technology to pharmaceutical, biotechnology, and research clients developing ophthalmic therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOklahoma City, United States
HQ citystring
Oklahoma City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical ophthalmic research, contract research services, ophthalmic drug delivery, bioanalytical services, ophthalmic animal models
Industry3 codes
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Preclinical Contract Research Services
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

EyeCRO provides preclinical ophthalmic research services including in-life efficacy studies, toxicology/PK studies, and bioanalytical analysis (LC-MS/MS, HPLC, ELISA) under one roof. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.

eyecro.com
2MiDROPS Technology Licensing
TypeLicensing Royalties
Description

EyeCRO licenses its MiDROPS microemulsion drug delivery platform to pharmaceutical partners. Receives tiered single-digit royalties on commercialized products for ophthalmologic indications as well as development and regulatory milestones. Notable licensees include NeuMedics (NM108) and InMed Pharmaceuticals (cannabinoids).

eyecro.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1MiDROPS®
Description

Microemulsion Drug Ocular Penetration System - a proprietary technology for eyedrop formulations of small molecules that are lipophilic, enabling delivery to both anterior and posterior segments of the eye.

eyecro.com
Core offering1 text field

EyeCRO is a preclinical ophthalmic contract research organization providing a fully integrated platform combining in-life efficacy studies, bioanalytical analysis (LC-MS/MS, HPLC, ELISA), toxicology/PK studies, and eyedrop formulation development under one roof. The company operates the proprietary MiDROPS microemulsion drug delivery technology platform, licensed to pharmaceutical partners for lipophilic small molecule ocular delivery. Services are delivered from AAALAC-accredited facilities in Oklahoma City, OK and Ann Arbor, MI, supported by 22+ validated preclinical disease models.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Standard curves validated with 12 to 20 points per analyte, typical R² values of 0.997 or higher
+3 more records
Product overview1 text field

EyeCRO is a preclinical ophthalmic contract research organization providing a fully integrated platform for ophthalmic drug development. The core offering combines MiDROPS® (proprietary microemulsion drug delivery technology) with comprehensive research services including bioanalytical services (LC-MS/MS), dosing and drug delivery, histology and pathology, ophthalmic imaging and physiology, and proprietary software analysis (EyeQ). The company maintains a library of 22+ validated preclinical disease models spanning retinal, corneal, inflammatory, and optic nerve indications. Services are delivered from facilities in Oklahoma City (headquarters) and Ann Arbor, Michigan, with all studies supported by AAALAC International accreditation.

Product and service6 records
1EyeCRO Preclinical Research Services
CategoryContract Research Services
Description

Fully integrated preclinical ophthalmic contract research platform providing in-life efficacy studies, toxicology/PK studies, bioanalytical analysis, and eyedrop formulation development for pharmaceutical, biotechnology, and academic sponsors developing ophthalmic therapeutics.

2MiDROPS
CategoryDrug Delivery Technology Platform
Description

Proprietary Microemulsion Drug Ocular Penetration System (microemulsion drug delivery technology) enabling eyedrop formulations of lipophilic small molecules for delivery to both anterior and posterior eye segments. Licensed to pharmaceutical partners with tiered single-digit royalties and development milestones.

3Bioanalytical Services
CategoryBioanalytical Laboratory Services
Description

Bioanalytical services utilizing LC-MS/MS, HPLC, ELISA, automated sample preparation (Waters Andrew+), multiplex immunoassay, and protein quantification from ocular tissues and fluids. Includes optimized ocular tissue extraction protocols for mouse, rat, and rabbit, with standard curves of 12-20 points per analyte (typical R² 0.997 or higher).

4Dosing & Drug Delivery
CategoryPreclinical Dosing Services
Description

Comprehensive ocular, topical, intranasal, and systemic dosing routes across mouse, rat, and rabbit including intravitreal, intracameral, subconjunctival, subretinal, suprachoroidal, and topical eye drop administration for preclinical studies.

5Histology & Pathology
CategoryHistopathology Services
Description

Full histological processing, H&E staining, immunohistochemistry (IHC), and digital image quantification for ocular tissue analysis including paraffin sections, plastic sections, retinal flatmounts, and vascular labeling.

6Ophthalmic Imaging & Physiology
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-16
Description

NIH-Industry collaboration advancing gene-agnostic treatment for retinal disease using reserpine. EyeCRO contributed to preclinical studies demonstrating reserpine's protective effect on retinal neurons in inherited blinding diseases.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-22
Description

Collaboration with Dr. Anand Swaroop's laboratory at the National Eye Institute on research published in eLife, studying gene-agnostic treatments for inherited retinal degenerations. Also collaborated on reserpine study for inherited blinding diseases.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-12-03
Description

Worldwide license for InMed to formulate any cannabinoid molecule using MiDROPS for ophthalmic instillation. EyeCRO receives licensing fees and royalties on commercialized products.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2017-05-01
Description

Collaboration to develop and commercialize large mammalian preclinical models for ophthalmic diseases including Age-Related Macular Degeneration and Diabetic Retinopathy. EyeCRO provides expertise in new model development; MPI Research contributes specialized ophthalmology capabilities and large mammalian study capacity.

Strategic tierCoreTypeOthersAnnounced on2015-06-29
Description

Charlesson LLC is the parent company that spun off EyeCRO (Eye Contract Research Organization). Dr. Rafal Farjo is CEO of both companies. Charlesson developed the MiDROPS technology with SBIR grants from HHS.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2015-05-04
Description

Collaboration granting NeuMedics full access to the MiDROPS formulation platform for development of NM108, a first-in-class small molecule for ophthalmic disorders including Diabetic Retinopathy. EyeCRO receives tiered single-digit royalties on commercialized products and development milestones.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2013-06-10
Description

Strategic partnership to expedite preclinical drug development activities, facilitating seamless transition from discovery and non-GLP stage to performance of GLP IND-enabling studies in ocular research.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Longstanding partnership allowing EyeCRO to access academic resources while providing mutual benefits to the University. Originated from Charlesson which was founded by a University of Oklahoma faculty professor.

9SparingVision
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EyeCRO contributed to the pharmacology and safety evaluation of SPVN06, SparingVision's mutation-independent gene therapy for rod-cone dystrophies, supporting the ongoing Phase I/II PRODYGY trial.

eyecro.com
10Telios Pharma
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EyeCRO's MiDROPS technology was used in Telios Pharma's TL-925 clinical trials for dry eye disease, achieving successful Phase 2 results. This marked the first clinical application of the MiDROPS technology.

eyecro.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

EyeCRO CEO Dr. Rafal Farjo served as co-author on a publication validating a cell-based potency assay for LUXTURNA, the first gene therapy approved in the U.S. for an inherited retinal disease.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a partner on EyeCRO's Partners page. Catalent is the leading global provider of advanced delivery technologies with an ophthalmic center-of-excellence for BFS manufacturing.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Listed as a partner providing histology and IHC data services, working closely with clients and boarded pathologists for image analysis.

14Little Creek Research
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Listed as a partner providing nonclinical pharmacology, pharmacokinetics, toxicology, and medical writing services with emphasis on ophthalmic drug products.

eyecro.com
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Listed as a partner providing strategic product development planning, particularly in local therapy (ophthalmology and dermatology).

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Listed as a partner, a niche ophthalmology CRO with clinical trial capabilities. Trial Runners could serve as a referral or complementary service provider in the clinical stage.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Iris Pharma is a preclinical and clinical ophthalmic CRO offering animal models, pharmacology, and toxicology services for ocular drug development. Comparable to EyeCRO in preclinical model breadth and specialization in ophthalmology, with a European geographic footprint.

TypeDirect peer
Description

Ora is a leading ophthalmic-focused CRO providing preclinical and clinical research services for ocular therapeutics, including animal models, pharmacokinetics, and clinical development. It is the closest direct competitor to EyeCRO in the ophthalmic preclinical CRO segment, though with greater clinical-stage breadth.

TypeBroad incumbent
Description

Labcorp (formerly Covance) provides preclinical and clinical CRO services including ophthalmic toxicology and PK capabilities. As a diversified global CRO, it competes with EyeCRO for non-specialized preclinical ophthalmic work, particularly from large pharma sponsors.

TypeDirect peer
Description

Experimentica is a preclinical ophthalmic CRO offering in vivo ocular models, pharmacology, and toxicology services across multiple species. Comparable to EyeCRO in specialized preclinical ophthalmic research with similar model breadth.

TypeBroad incumbent
Description

WuXi AppTec is a large global CRO/CDMO with preclinical research services that includes ophthalmic capabilities. As a broad incumbent, it competes for outsourced preclinical work from biotech sponsors seeking integrated discovery-to-development services.

TypeDirect peer
Description

MPI Research is a preclinical CRO specializing in ophthalmology among other therapeutic areas, and is an existing strategic partner of EyeCRO for large mammalian ophthalmic models. Overlapping capabilities make it both a competitor and collaborator.

TypeBroad incumbent
Description

Pharmaron is a global CRO/CDMO with preclinical ophthalmic capabilities and integrated drug discovery and development services. A broad incumbent competing for outsourced ophthalmic preclinical work from emerging biotech sponsors.

TypeBroad incumbent
Description

Charles River is a global preclinical CRO with broad ophthalmic capabilities through its research models and discovery services segments. A broad incumbent competing with EyeCRO for ophthalmic preclinical work, though not specialized to the same degree.

9Absorption Systems
TypeDirect peer
Description

Absorption Systems is a preclinical CRO with bioanalytical and ocular drug development services including pharmacokinetics and formulation work. Comparable to EyeCRO in bioanalytical capabilities for ophthalmic programs.

TypeDirect peer
Description

Calvert Labs is a preclinical CRO with ocular research capabilities and an existing strategic partner of EyeCRO. Provides general and ocular preclinical drug development services, including GLP IND-enabling studies, making it both a peer and a collaborator.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EyeCRO

Preclinical Contract Research Serviceseyecro.com

EyeCRO is a preclinical ophthalmic contract research organization providing integrated in-life efficacy studies, bioanalytical services, and the proprietary MiDROPS microemulsion drug delivery technology to pharmaceutical, biotechnology, and research clients developing ophthalmic therapeutics.

What EyeCRO does

EyeCRO LLC is a preclinical ophthalmic contract research organization founded in 2012 as a spin-off from Charlesson LLC and headquartered in Oklahoma City, Oklahoma, with a secondary research and development laboratory in Ann Arbor, Michigan. The company provides an integrated preclinical research platform for ophthalmic drug development, combining in-life efficacy studies, toxicology and pharmacokinetics, and in-house bioanalytical analysis (LC-MS/MS, HPLC, ELISA) under one roof, supported by 22+ validated disease models spanning retinal, corneal, inflammatory, and optic nerve indications across mouse, rat, and rabbit species. Both facilities hold full AAALAC International accreditation and EyeCRO has served over 400 companies and research institutions worldwide since inception.

The company's differentiator is the proprietary MiDROPS® microemulsion drug delivery technology, covered by broad US and international patents, which enables eyedrop delivery of lipophilic small molecules to both anterior and posterior segments of the eye. EyeCRO also offers EyeQ, a proprietary automated retinal ganglion cell quantification software, and provides specialized capabilities including dosing across multiple routes (intravitreal, subretinal, subconjunctival, topical), in-vivo ophthalmic imaging (ERG, OCT, fundus photography, fluorescein angiography), and histology services.

EyeCRO generates revenue through two streams: B2B contract research services delivered on a project-based, quote-based model to pharmaceutical and biotechnology sponsors (with named clients including SparingVision, Telios Pharma, InMed Pharmaceuticals, NeuMedics, and the National Eye Institute), and licensing of the MiDROPS platform to pharma partners for ophthalmic drug formulations, generating tiered single-digit royalties and development milestones. Distribution is direct enterprise sales, supported by presence at the ARVO Annual Meeting, scientific publications, and professional social media. The company is privately held and operates as a subsidiary of Charlesson LLC under CEO Dr. Rafal Farjo.

EyeCRO firmographics

Firmographics
Name
EyeCRO
Legal name
EyeCRO LLC
Website
https://eyecro.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
EyeCRO is a preclinical ophthalmic contract research organization providing integrated in-life efficacy studies, bioanalytical services, and the proprietary MiDROPS microemulsion drug delivery technology to pharmaceutical, biotechnology, and research clients developing ophthalmic therapeutics.
Ownership category
akta.pro rank

EyeCRO industry classification

Industry
Product category
Preclinical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAIAAAL
Ophthalmology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Preclinical ophthalmic research
  • Contract research services
  • Ophthalmic drug delivery
  • Bioanalytical services
  • Ophthalmic animal models

Where EyeCRO is headquartered

Location

Headquarters

HQ city
Oklahoma City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

EyeCRO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: EyeCRO provides preclinical ophthalmic research services including in-life efficacy studies, toxicology/PK studies, and bioanalytical analysis (LC-MS/MS, HPLC, ELISA) under one roof. Revenue is generated through project-based contracts with pharmaceutical and biotech companies.
  2. MiDROPS Technology Licensing: EyeCRO licenses its MiDROPS microemulsion drug delivery platform to pharmaceutical partners. Receives tiered single-digit royalties on commercialized products for ophthalmologic indications as well as development and regulatory milestones. Notable licensees include NeuMedics (NM108) and InMed Pharmaceuticals (cannabinoids).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

EyeCRO product offering

Product offering

Core offering

EyeCRO is a preclinical ophthalmic contract research organization providing a fully integrated platform combining in-life efficacy studies, bioanalytical analysis (LC-MS/MS, HPLC, ELISA), toxicology/PK studies, and eyedrop formulation development under one roof. The company operates the proprietary MiDROPS microemulsion drug delivery technology platform, licensed to pharmaceutical partners for lipophilic small molecule ocular delivery. Services are delivered from AAALAC-accredited facilities in Oklahoma City, OK and Ann Arbor, MI, supported by 22+ validated preclinical disease models.

Product overview

EyeCRO is a preclinical ophthalmic contract research organization providing a fully integrated platform for ophthalmic drug development. The core offering combines MiDROPS® (proprietary microemulsion drug delivery technology) with comprehensive research services including bioanalytical services (LC-MS/MS), dosing and drug delivery, histology and pathology, ophthalmic imaging and physiology, and proprietary software analysis (EyeQ). The company maintains a library of 22+ validated preclinical disease models spanning retinal, corneal, inflammatory, and optic nerve indications. Services are delivered from facilities in Oklahoma City (headquarters) and Ann Arbor, Michigan, with all studies supported by AAALAC International accreditation.

Differentiator

Problem solved

Functional benefit

Brands

  • MiDROPS®: Microemulsion Drug Ocular Penetration System - a proprietary technology for eyedrop formulations of small molecules that are lipophilic, enabling delivery to both anterior and posterior segments of the eye.

Products and services

  • EyeCRO Preclinical Research Services Fully integrated preclinical ophthalmic contract research platform providing in-life efficacy studies, toxicology/PK studies, bioanalytical analysis, and eyedrop formulation development for pharmaceutical, biotechnology, and academic sponsors developing ophthalmic therapeutics.
  • MiDROPS Proprietary Microemulsion Drug Ocular Penetration System (microemulsion drug delivery technology) enabling eyedrop formulations of lipophilic small molecules for delivery to both anterior and posterior eye segments. Licensed to pharmaceutical partners with tiered single-digit royalties and development milestones.
  • Bioanalytical Services Bioanalytical services utilizing LC-MS/MS, HPLC, ELISA, automated sample preparation (Waters Andrew+), multiplex immunoassay, and protein quantification from ocular tissues and fluids. Includes optimized ocular tissue extraction protocols for mouse, rat, and rabbit, with standard curves of 12-20 points per analyte (typical R² 0.997 or higher).
  • Dosing & Drug Delivery Comprehensive ocular, topical, intranasal, and systemic dosing routes across mouse, rat, and rabbit including intravitreal, intracameral, subconjunctival, subretinal, suprachoroidal, and topical eye drop administration for preclinical studies.
  • Histology & Pathology Full histological processing, H&E staining, immunohistochemistry (IHC), and digital image quantification for ocular tissue analysis including paraffin sections, plastic sections, retinal flatmounts, and vascular labeling.
  • Ophthalmic Imaging & Physiology

Quantifiable outcome

  • Standard curves validated with 12 to 20 points per analyte, typical R² values of 0.997 or higher
  • +3 more outcomes

Companies that use EyeCRO

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles4 records

EyeCRO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

EyeCRO partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core and minor.

  • National Institutes of Health (NIH)coreStrategic or Co-development Partner · 16 April 2025NIH-Industry collaboration advancing gene-agnostic treatment for retinal disease using reserpine. EyeCRO contributed to preclinical studies demonstrating reserpine's protective effect on retinal neurons in inherited blinding diseases.
  • National Eye Institute (NIH)coreStrategic or Co-development Partner · 22 January 2025Collaboration with Dr. Anand Swaroop's laboratory at the National Eye Institute on research published in eLife, studying gene-agnostic treatments for inherited retinal degenerations. Also collaborated on reserpine study for inherited blinding diseases.
  • InMed PharmaceuticalscoreOEM/ Whitelabel/ Licensing Partner · 3 December 2020Worldwide license for InMed to formulate any cannabinoid molecule using MiDROPS for ophthalmic instillation. EyeCRO receives licensing fees and royalties on commercialized products.
  • MPI ResearchcoreStrategic or Co-development Partner · 1 May 2017Collaboration to develop and commercialize large mammalian preclinical models for ophthalmic diseases including Age-Related Macular Degeneration and Diabetic Retinopathy. EyeCRO provides expertise in new model development; MPI Research contributes specialized ophthalmology capabilities and large mammalian study capacity.
  • Charlesson LLCcoreOthers · 29 June 2015Charlesson LLC is the parent company that spun off EyeCRO (Eye Contract Research Organization). Dr. Rafal Farjo is CEO of both companies. Charlesson developed the MiDROPS technology with SBIR grants from HHS.
  • NeuMedicscoreOEM/ Whitelabel/ Licensing Partner · 4 May 2015Collaboration granting NeuMedics full access to the MiDROPS formulation platform for development of NM108, a first-in-class small molecule for ophthalmic disorders including Diabetic Retinopathy. EyeCRO receives tiered single-digit royalties on commercialized products and development milestones.
  • Calvert LabscoreStrategic or Co-development Partner · 10 June 2013Strategic partnership to expedite preclinical drug development activities, facilitating seamless transition from discovery and non-GLP stage to performance of GLP IND-enabling studies in ocular research.
  • University of Oklahoma Health Sciences CenterminorStrategic or Co-development PartnerLongstanding partnership allowing EyeCRO to access academic resources while providing mutual benefits to the University. Originated from Charlesson which was founded by a University of Oklahoma faculty professor.
  • SparingVisioncoreStrategic or Co-development PartnerEyeCRO contributed to the pharmacology and safety evaluation of SPVN06, SparingVision's mutation-independent gene therapy for rod-cone dystrophies, supporting the ongoing Phase I/II PRODYGY trial.
  • Telios PharmacoreStrategic or Co-development PartnerEyeCRO's MiDROPS technology was used in Telios Pharma's TL-925 clinical trials for dry eye disease, achieving successful Phase 2 results. This marked the first clinical application of the MiDROPS technology.
  • Spark TherapeuticsminorStrategic or Co-development PartnerEyeCRO CEO Dr. Rafal Farjo served as co-author on a publication validating a cell-based potency assay for LUXTURNA, the first gene therapy approved in the U.S. for an inherited retinal disease.
  • CatalentminorStrategic or Co-development PartnerListed as a partner on EyeCRO's Partners page. Catalent is the leading global provider of advanced delivery technologies with an ophthalmic center-of-excellence for BFS manufacturing.
  • Histotox LabsminorImplementation/ SI/ Consulting PartnerListed as a partner providing histology and IHC data services, working closely with clients and boarded pathologists for image analysis.
  • Little Creek ResearchminorImplementation/ SI/ Consulting PartnerListed as a partner providing nonclinical pharmacology, pharmacokinetics, toxicology, and medical writing services with emphasis on ophthalmic drug products.
  • PharmaLogic DevelopmentminorImplementation/ SI/ Consulting PartnerListed as a partner providing strategic product development planning, particularly in local therapy (ophthalmology and dermatology).
  • Trial RunnersminorChannel Partner/ Reseller/ DistributorListed as a partner, a niche ophthalmology CRO with clinical trial capabilities. Trial Runners could serve as a referral or complementary service provider in the clinical stage.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

EyeCRO competitors and assessment

Company assessment

Direct peers

  • Iris Pharma: Iris Pharma is a preclinical and clinical ophthalmic CRO offering animal models, pharmacology, and toxicology services for ocular drug development. Comparable to EyeCRO in preclinical model breadth and specialization in ophthalmology, with a European geographic footprint.
  • Ora, Inc. Ora is a leading ophthalmic-focused CRO providing preclinical and clinical research services for ocular therapeutics, including animal models, pharmacokinetics, and clinical development. It is the closest direct competitor to EyeCRO in the ophthalmic preclinical CRO segment, though with greater clinical-stage breadth.
  • Experimentica (now part of PharmaLegacy): Experimentica is a preclinical ophthalmic CRO offering in vivo ocular models, pharmacology, and toxicology services across multiple species. Comparable to EyeCRO in specialized preclinical ophthalmic research with similar model breadth.
  • MPI Research: MPI Research is a preclinical CRO specializing in ophthalmology among other therapeutic areas, and is an existing strategic partner of EyeCRO for large mammalian ophthalmic models. Overlapping capabilities make it both a competitor and collaborator.
  • Absorption Systems: Absorption Systems is a preclinical CRO with bioanalytical and ocular drug development services including pharmacokinetics and formulation work. Comparable to EyeCRO in bioanalytical capabilities for ophthalmic programs.
  • Calvert Labs: Calvert Labs is a preclinical CRO with ocular research capabilities and an existing strategic partner of EyeCRO. Provides general and ocular preclinical drug development services, including GLP IND-enabling studies, making it both a peer and a collaborator.

Broad incumbents

  • Labcorp Drug Development (Covance): Labcorp (formerly Covance) provides preclinical and clinical CRO services including ophthalmic toxicology and PK capabilities. As a diversified global CRO, it competes with EyeCRO for non-specialized preclinical ophthalmic work, particularly from large pharma sponsors.
  • WuXi AppTec: WuXi AppTec is a large global CRO/CDMO with preclinical research services that includes ophthalmic capabilities. As a broad incumbent, it competes for outsourced preclinical work from biotech sponsors seeking integrated discovery-to-development services.
  • Pharmaron: Pharmaron is a global CRO/CDMO with preclinical ophthalmic capabilities and integrated drug discovery and development services. A broad incumbent competing for outsourced ophthalmic preclinical work from emerging biotech sponsors.
  • Charles River Laboratories: Charles River is a global preclinical CRO with broad ophthalmic capabilities through its research models and discovery services segments. A broad incumbent competing with EyeCRO for ophthalmic preclinical work, though not specialized to the same degree.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

EyeCRO social profiles

Digital presence

EyeCRO compliance and trust

Trust signal

Compliance2 records

EyeCRO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EyeCRO leadership team

Management profile

Number of profiles

Profiles2 records

EyeCRO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EyeCRO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EyeCRO

What does EyeCRO do?

EyeCRO is a preclinical ophthalmic contract research organization providing a fully integrated platform combining in-life efficacy studies, bioanalytical analysis (LC-MS/MS, HPLC, ELISA), toxicology/PK studies, and eyedrop formulation development under one roof. The company operates the proprietary MiDROPS microemulsion drug delivery technology platform, licensed to pharmaceutical partners for lipophilic small molecule ocular delivery. Services are delivered from AAALAC-accredited facilities in Oklahoma City, OK and Ann Arbor, MI, supported by 22+ validated preclinical disease models.

Is EyeCRO a public or private company?

EyeCRO is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was EyeCRO founded?

EyeCRO was founded in 2012. It employs 11 to 50 people.

Where is EyeCRO based?

EyeCRO is headquartered in Oklahoma City, United States, in the North America region.

How does EyeCRO make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are miDROPS Technology Licensing.

Who are EyeCRO's main competitors?

Direct peers on record are Iris Pharma, Ora, Inc., Experimentica (now part of PharmaLegacy), MPI Research, Absorption Systems and Calvert Labs. Broad incumbents are Labcorp Drug Development (Covance), WuXi AppTec, Pharmaron and Charles River Laboratories.

Does EyeCRO have an API?

No public API is recorded for EyeCRO.

What industry is EyeCRO in?

EyeCRO's product category is Preclinical Contract Research Services. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals